A Faster, Longer-Lasting Wrinkle Relaxer Moves Closer to FDA Approval
NewBeauty Facebook Pinterest Instagram Youtube find a doctor Face Adult Acne Antioxidants Anti-Aging Celebrity Chronic Skin Conditions Eye Hydration Hyperpigmentation Makeup View All Eyebrows Eye Color Foundation Fragrance Lip Color Makeovers Male Skin Care Peels Pre-Event Prep Sensitive Skin Skin Care Skin Health Smile Sun Care Treatments Fillers Microneedling Post-Procedure Skin Care Neurotoxins Regenerative Aesthetics Skin Lifting Body Body Sculpting Breasts Butts Cellulite Hair Removal Hands + Nails Legs Pregnancy Find a Doctor Hair Bond Repair Celebrity Dry Hair Frizzy Hair Gray Hair Hair Color Hair Growth Hair Repair Scalp Health Styling + Tips Awards NB100 Awards 15th Annual Beauty Awards 2025 NewBeauty Readers’ Choice Awards Shopping Gift Guides Product Reviews NewBeauty Storefront Wellness Fitness GLP-1s Health Menopause About Us TESTTUBE Search for: Search HomeCosmetic Treatments A Faster, Longer-Lasting Wrinkle Relaxer Moves Closer to FDA Approval Faster, longer and different. Tatiana Bido Updated: Feb 2, 2026 fizkes / Getty Images In This Article How long does Relfydess last?How It’s DifferentWhat Galderma SaysWhen will Relfydess be available? UPDATE (February 2026): Galderma announced that the U.S. Food and Drug Administration has accepted the Biologics License Application resubmission for RelabotulinumtoxinA, a key regulatory step toward potential U.S. approval. “We pioneered the development of RelabotulinumtoxinA to address the growing demand for faster-acting and longer-lasting anti-wrinkle solutions,” said Dr. Baldo Scassellati Sforzolini, Galderma’s Global Head of R&D, in a press release. “We’re excited about the potential to bring this innovative neuromodulator to the U.S.” At the IMCAS 2025 conference in Paris, Galderma presented new data on its yet-to-be-released injectable, RelabotulinumtoxinA, or Relfydess, which is generating buzz for its potential to work faster and last longer than existing wrinkle relaxers. According to the company, some patients in a phase IIIb trial—an advanced study conducted before regulatory approval—saw visible results as early as Day 1 after treatment. That could set it…